Ghassan K. Abou-Alfa, MD, on HCC: Results From the CELESTIAL Trial

2018 Gastrointestinal Cancers Symposium
Tweet this page

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings on cabozantinib vs placebo in patients with advanced hepatocellular carcinoma who have received prior treatment with sorafenib (Abstract 207).

Advertisement

Advertisement



Advertisement